All relevant data are within the paper and its Supporting Information files.

Introduction {#sec004}
============

Infection with *Trypanosoma cruzi* is a complex zoonosis, transmitted by more than 130 triatomine species and sustained by over 70 genera of mammalian reservoir hosts. *T*. *cruzi* has a broad endemic range that extends from the Southern United States to Argentinean Patagonia. The human infection, which may lead to Chagas disease, is the most important parasitic infection in Latin America with serious consequences for public health and national economies.

The diversity of the *T*. *cruzi* genome is well recognized \[[@pntd.0003765.ref001]--[@pntd.0003765.ref003]\]. Designation of ecologically and epidemiologically relevant groups for *T*. *cruzi* has oscillated between a few discrete groups \[[@pntd.0003765.ref004]\] and many \[[@pntd.0003765.ref005]\]. Currently, six Discrete Typing Units (DTUs) are defined \[[@pntd.0003765.ref002]\]. In 2009, these DTUs were renamed by consensus as TcI--TcVI \[[@pntd.0003765.ref006]\]. Several reviews already describe how these DTUs correspond with former nomenclatures and with prospective biological and host associations \[[@pntd.0003765.ref006]--[@pntd.0003765.ref008]\]. All six DTUs are known to be infective to humans and to cause Chagas disease. Further, in patients infected with DTU mixtures, different tissue distribution has been detected \[[@pntd.0003765.ref009]--[@pntd.0003765.ref011]\]. Recently a new genotype associated with anthropogenic bats (TcBat) has been detected in Brazil, Panama and Colombia and awaits further characterization for definitive DTU assignment \[[@pntd.0003765.ref012]--[@pntd.0003765.ref014]\].

The standardized nomenclature for *T*. *cruzi* DTUs should improve scientific communication and guide future research on comparative epidemiology and pathology. However, a straightforward and reproducible DTU genotyping strategy is still required. Numerous approaches have been proposed to characterize the biochemical and genetic diversity of *T*. *cruzi* isolates \[[@pntd.0003765.ref015]--[@pntd.0003765.ref023]\] with variable levels of complexity, selectivity and analytical sensitivity. Due to sensitivity constraints, most of these strategies have been applied only to cultured stocks and not directly to biological or clinical samples. Thus, their results may have underestimated parasite diversity due to possible strain selection during culture expansion \[[@pntd.0003765.ref024]--[@pntd.0003765.ref025]\]. Some methods require multiple sequential conventional PCR reactions, PCR-RFLP, hybridization or post-PCR sequencing steps; these tests are cumbersome and time-consuming, and their results are often difficult to interpret. Accordingly, we aimed to develop a novel multiplex Real-Time PCR method using TaqMan probes, allowing distinction of the six DTUs in a few steps not only from cultured stocks but also from a high proportion of biological and clinical samples.

Materials and Methods {#sec005}
=====================

Biological Samples {#sec006}
------------------

Reference strains: Genomic DNA from a panel of reference stocks representative of the 6 *T*. *cruzi* DTUs, *Trypanosoma rangeli* and *Leishmania* spp. was used for analytical validation of the assay ([Table 1](#pntd.0003765.t001){ref-type="table"}).

10.1371/journal.pntd.0003765.t001

###### *T*. *cruzi*, *T*. *rangeli* and *Leishmania* spp. isolates used to evaluate the analytical performance of the multiplex real-time PCR genotyping assays.

![](pntd.0003765.t001){#pntd.0003765.t001g}

  Strain                                               DTU/Species           Origin      Vector/Host
  ---------------------------------------------------- --------------------- ----------- -----------------------------
  K-98[^a^](#t001fn001){ref-type="table-fn"}           TcI                   Argentina   *Homo sapiens*
  PalDa30[^b^](#t001fn001){ref-type="table-fn"}        TcI                   Argentina   *Didelphis albiventris*
  SE9V[^c^](#t001fn001){ref-type="table-fn"}           TcI                   Argentina   *Homo sapiens*
  TCC[^d^](#t001fn001){ref-type="table-fn"}            TcI                   Chile       *Homo sapiens*
  13379 cl7[^e^](#t001fn001){ref-type="table-fn"}      TcI                   Bolivia     *Homo sapiens*
  G[^a^](#t001fn001){ref-type="table-fn"}              TcI                   Brazil      *Didelphis marsupialis*
  Sylvio X10[^a^](#t001fn001){ref-type="table-fn"}     TcI                   Brazil      *Homo sapiens*
  Triatoma[^f^](#t001fn001){ref-type="table-fn"}       TcI                   Mexico      *Triatoma sp*.
  Duran[^f^](#t001fn001){ref-type="table-fn"}          TcI                   Mexico      nd
  Gamma[^f^](#t001fn001){ref-type="table-fn"}          TcI                   Mexico      nd
  Colombiana[^a^](#t001fn001){ref-type="table-fn"}     TcI                   Colombia    *Homo sapiens*
  Dm28c[^a^](#t001fn001){ref-type="table-fn"}          TcI                   Venezuela   *Didelphis marsupialis*
  OPS21cl11[^g^](#t001fn001){ref-type="table-fn"}      TcI                   Venezuela   *Homo sapiens*
  Tu18[^a^](#t001fn001){ref-type="table-fn"}           TcII                  Bolivia     *Triatoma infestans*
  Basileu[^h^](#t001fn001){ref-type="table-fn"}        TcII                  Brazil      *Homo sapiens*
  Y^a^                                                 TcII                  Brazil      *Homo sapiens*
  MAS cl1[^a^](#t001fn001){ref-type="table-fn"}        TcII                  Brazil      *Homo sapiens*
  Ll51-P24-Ro[^i^](#t001fn001){ref-type="table-fn"}    TcIII                 Argentina   *Canis familiaris*
  M5631 cl5[^a^](#t001fn001){ref-type="table-fn"}      TcIII                 Brazil      *Dasypus novemcinctus*
  M6241 cl6[^a^](#t001fn001){ref-type="table-fn"}      TcIII                 Brazil      *Homo sapiens*
  3663[^a^](#t001fn001){ref-type="table-fn"}           TcIII                 Brazil      *Panstrongylus geniculatus*
  X109/2[^a^](#t001fn001){ref-type="table-fn"}         TcIII                 Paraguay    *Canis familiaris*
  CanIII[^a^](#t001fn001){ref-type="table-fn"}         TcIV                  Brazil      *Homo sapiens*
  4167[^a^](#t001fn001){ref-type="table-fn"}           TcIV                  Brazil      *Rhodnius brethesi*
  Griffin[^j^](#t001fn001){ref-type="table-fn"}        TcIV                  USA         *Canis familiaris*
  Dog Theis[^a^](#t001fn001){ref-type="table-fn"}      TcIV                  USA         *Canis familiaris*
  92122102R[^a^](#t001fn001){ref-type="table-fn"}      TcIV                  USA         *Procyon lotor*
  PAH265[^k^](#t001fn001){ref-type="table-fn"}         TcV                   Argentina   *Homo sapiens*
  PAH179[^k^](#t001fn001){ref-type="table-fn"}         TcV                   Argentina   *Homo sapiens*
  LL014-1R1cl1[^l^](#t001fn001){ref-type="table-fn"}   TcV                   Argentina   nd
  MN cl2[^a^](#t001fn001){ref-type="table-fn"}         TcV                   Chile       *Homo sapiens*
  SO3 cl5[^a^](#t001fn001){ref-type="table-fn"}        TcV                   Bolivia     *Triatoma infestans*
  RA[^a^](#t001fn001){ref-type="table-fn"}             TcVI                  Argentina   *Homo sapiens*
  Tep7[^k^](#t001fn001){ref-type="table-fn"}           TcVI                  Argentina   *Canis familiaris*
  Tep6 cl5[^k^](#t001fn001){ref-type="table-fn"}       TcVI                  Argentina   *Canis familiaris*
  LL052[^m^](#t001fn001){ref-type="table-fn"}          TcVI                  Argentina   nd
  Tulahuen cl2[^a^](#t001fn001){ref-type="table-fn"}   TcVI                  Chile       *Homo sapiens*
  CL Brener[^a^](#t001fn001){ref-type="table-fn"}      TcVI                  Brazil      *Triatoma infestans*
  Peruana[^n^](#t001fn001){ref-type="table-fn"}        TcVI                  Perú        nd
  444[^o^](#t001fn001){ref-type="table-fn"}            *T*. *rangeli*        Colombia    *Rhodnius prolixus*
  SC-58[^p^](#t001fn001){ref-type="table-fn"}          *T*. *rangeli*        Brazil      *Echimys dasythrix*
  Tre[^q^](#t001fn001){ref-type="table-fn"}            *T*. *rangeli*        Colombia    nd
  L1566[^r^](#t001fn001){ref-type="table-fn"}          *L*. *major*          Ecuador     *Homo sapiens*
  M2269[^s^](#t001fn001){ref-type="table-fn"}          *L*. *amazonensis*    Brazil      *Homo sapiens*
  L1569[^r^](#t001fn001){ref-type="table-fn"}          *L*. *brasiliensis*   Ecuador     *Homo sapiens*
  L1508[^r^](#t001fn001){ref-type="table-fn"}          *L*. *mexicana*       Belize      *Homo sapiens*

References: ^a^\[[@pntd.0003765.ref006]\]; ^b^\[[@pntd.0003765.ref026]\]; ^c^\[[@pntd.0003765.ref027]\]; ^d^\[[@pntd.0003765.ref028]\]; ^e^\[[@pntd.0003765.ref029]\]; ^f^\[[@pntd.0003765.ref030]\]; ^g^\[[@pntd.0003765.ref031]\]; ^h^\[[@pntd.0003765.ref032]\]; ^i^\[[@pntd.0003765.ref033]\] ^j^\[[@pntd.0003765.ref034]\]; ^k^\[[@pntd.0003765.ref022]\]; ^l^\[[@pntd.0003765.ref023]\]; ^m^\[[@pntd.0003765.ref035]\]; ^n^\[[@pntd.0003765.ref036]\]; ^o^\[[@pntd.0003765.ref037]\]; ^p^\[[@pntd.0003765.ref038]\]; ^q^\[[@pntd.0003765.ref039]\]; ^r^\[[@pntd.0003765.ref040]\]; ^s^\[[@pntd.0003765.ref041]\]. DTU, Discrete Typing Unit; nd, no data.

Clinical specimens: A total of 132 clinical samples were included in the study: one tissue sample and 131 peripheral blood samples obtained from acute *T*. *cruzi* infected patients (AI, n = 13), asymptomatic (ACD, n = 64) and symptomatic (SCD, n = 27, 19 cardiac, 5 digestive and 3 mixed disease patients) chronic Chagas disease patients, congenitally infected children (CI, n = 16), and from adult patients with clinical reactivation in the context of immunosuppression (RCD, n = 11) ([S1 Table](#pntd.0003765.s001){ref-type="supplementary-material"}).

Triatomine samples: A total of 104 triatomine derived samples were included in the study: 16 culture isolates and 88 direct samples (38 abdomen/midgut samples and 50 feces/urine samples collected on filter paper) from infected bugs ([S2 Table](#pntd.0003765.s002){ref-type="supplementary-material"}).

Mammalian reservoir samples: A total of 71 samples obtained from *T*. *cruzi* reservoirs were included in the study: 27 culture isolates and 44 direct samples (38 peripheral blood samples and 6 heart explants) from mammalian reservoirs ([S3 Table](#pntd.0003765.s003){ref-type="supplementary-material"}).

Ethics Statement {#sec007}
----------------

The study with human samples was approved by the ethical committees of the participating institutions (Comité de Bioseguridad del INLASA, Ministerio de Salud de Bolivia; Comité de Ética en Investigación de la Universidad de Granada; Comité de Ética de Investigación del Instituto Nacional de Salud Pública de México; Comité de Ética del Hospital Italiano; Comité de Bioética del Hospital Universitario Fundación Favaloro; Comité de Bioética del Instituto de Medicina Regional de la Universidad Nacional del Nordeste; Comité de Bioética de la provincia de Jujuy), following the principles expressed in the Declaration of Helsinki. Written informed consents were obtained from the adult patients and from parents/guardians on behalf of all children participants.

DNA Extraction {#sec008}
--------------

Preparation of DNA from biological specimens was done according to the type of sample and the operating procedures followed by the laboratories from which DNA aliquots were obtained ([S1](#pntd.0003765.s001){ref-type="supplementary-material"}--[S3](#pntd.0003765.s003){ref-type="supplementary-material"} Tables). At our laboratory, peripheral blood and tissue samples were processed using High Pure PCR Template Preparation Kit (Roche, Germany) following the recommendations of the manufacturer. Triatomine feces impregnated on filter paper and abdomen samples were processed as reported \[[@pntd.0003765.ref042]\].

Conventional PCR Based Discrete Typing Unit Genotyping {#sec009}
------------------------------------------------------

Identification of *T*. *cruzi* DTUs was assessed using a conventional PCR algorithm for DTU genotyping, based on the amplification of three nuclear loci, the spliced leader intergenic region (SL-IR), the 24Sα-ribosomal DNA (24Sα-rDNA) and the A10 fragment, as reported \[[@pntd.0003765.ref011],[@pntd.0003765.ref017]\]. Analytical sensitivity for these methods was described in Burgos et al. (2007) \[[@pntd.0003765.ref017]\]: SL-IRac PCR: 1 pg, SL-IR I PCR: 5 pg, SL-IR II PCR: 5 pg, 24Sα-rDNA PCR: 100 fg, and A10 PCR: 1--10 pg DNA per reaction tube.

TaqMan Probes and Primer Design {#sec010}
-------------------------------

Multiple sequence alignments of the *T*. *cruzi* SL-IR, cytochrome oxidase subunit II (COII), 18S ribosomal DNA (18S rDNA) and 24Sα-rDNA genes were performed using the ClustalW algorithm in MEGA 5.2 software \[[@pntd.0003765.ref043]\]. Reference sequences were retrieved from the GenBank database. The PrimerQuest and OligoAnalyzer tools (provided online at the website [http://www.idtdna.com](http://www.idtdna.com/)) were used for the final design of specific primers and probes ([Table 2](#pntd.0003765.t002){ref-type="table"}). To minimize nonspecific detection, the oligonucleotides were compared with all relevant sequences using the BLAST database search program (provided online from the National Center for Biotechnology Information \[NCBI\]).

10.1371/journal.pntd.0003765.t002

###### Sequences and concentrations of primers and probes used in the multiplex real-time PCR assays.

![](pntd.0003765.t002){#pntd.0003765.t002g}

  PCR assay             Oligonucleotide                             Sequence (5\'- 3\')                         Final concentration (μM)
  --------------------- ------------------------------------------- ------------------------------------------- --------------------------
  **SL-IR MTq**         UTCC-Fw                                     CAGTTTCTGTACTATATTGGTACG                    0.5
                        TcI-Rv                                      CGATCAGCGCCACAGAAAGT                        0.5
                        TcII/V/VI-Rv                                GGAAAACACAGGAAGAAGC                         0.5
                        TcIII-Rv                                    CATTTTTATGAGGGGTTGTTCG                      0.5
                        TcIV-Rv                                     CATTTTTATTAGGGGTTGTACG                      0.5
                        TcI (probe)                                 FAM-CTC+CTTC+AT+GTT+TGT+GTCG-BHQ1           0.1
                        TcII/V/VI (probe)                           HEX-TATA+CC+CATATA+TATA+TA+GC-BHQ1          0.05
                        TcIII (probe)                               Quasar670-AATCGCG+TGTATGCACCGT-BHQ3         0.05
                        TcIV (probe)                                CAL Fluor Red610-GCCCCCGACGCCGTCCGTG-BHQ2   0.1
  **18S-COII MTq**      18S-Fw                                      ATGGGATAACAAAGGAGCAGCCTC                    0.2
                        18S-Rv                                      CTTCATTCCTGGATGCCGTGAGTT                    0.2
                        COII-Fw                                     ACACCTACCYGGTTCTCTACCT                      0.2
                        COII-Rv                                     CTYGARAGTGATTAYTTGGTGGGWG                   0.2
                        18S-TcII/VI (probe)                         FAM-CAGACTTCGGTCTTACCCTTCGCATCTCACA-BHQ1    0.05
                        18S-TcV (probe)                             HEX-TCTT+GCC+T+C+CGCATATTTTCACA-BHQ1        0.05
                        COII-TcII (probe)                           Cy5-AATGGATTACATCTACGGCTGACACCCA-BHQ3       0.1
  **24Sα-III/IV MTq**   D71[^a^](#t002fn001){ref-type="table-fn"}   AAGGTGCGTCGACAGTGTGG                        0.4
                        D76[^b^](#t002fn001){ref-type="table-fn"}   GGTTCTCTGTTGCCCCTTTT                        0.4
                        TcIII (probe)                               FAM-CTTTTCC+C+C+TCTCTTTTATTA+GG-BHQ1        0.2
                        TcIV (probe)                                HEX-+T+G+CTCTCTTTCCTTCTCTT+TACG-BHQ1        0.2

^a^\[[@pntd.0003765.ref044]\]; ^b^\[[@pntd.0003765.ref045]\]; SL-IR, spliced leader intergenic region; 18S, 18S-ribosomal ADN; COII, cytochrome oxidase II; 24Sα, 24Sα-ribosomal ADN; MTq, multiplex Real-Time PCR; BHQ, Black Hole Quencher. The + in front of the nucleotide indicates an LNA (Locked Nucleic Acid) monomer substitution.

Multiplex Real-Time PCR Assays {#sec011}
------------------------------

A Real-Time PCR flowchart for identification of *T*. *cruzi* DTUs in biological samples using TaqMan probes (MTq-PCR) is shown in [Fig 1](#pntd.0003765.g001){ref-type="fig"}. Oligonucleotide concentration and sequence information is detailed in [Table 2](#pntd.0003765.t002){ref-type="table"}. TaqMan probes were purchased from Integrated DNA Technologies, Inc. (USA). SL-IR and 18S-COII MTq-PCR assays were carried out using 1X QIAGEN Multiplex PCR Kit (QIAGEN, USA), while the 24Sα-III/IV MTq-PCR used 1X FastStart Universal Probe Master (Roche, Germany). All PCR reactions were carried out with 2 μL of resuspended DNA in a final volume of 20 μL. Optimal cycling conditions for the SL-IR and 18S-COII MTq-PCR assays were initially 15 min at 95°C followed by 40 cycles at 95°C for 30 sec and 60°C for 1 min in an Applied Biosystems (ABI 7500, USA) device. In turn, optimal cycling condition for the 24Sα-III/IV reaction was an initial cycle of 10 min at 95°C followed by 40 cycles at 95°C for 30 sec and 57°C for 1 min in a Rotor-Gene 6000 (Corbett, UK) device.

![Multiplex real-time PCR flowchart for identification of *Trypanosoma cruzi* DTUs in biological samples.\
SL-IR, spliced leader intergenic region; 18S, 18S-ribosomal ADN; COII, cytochrome oxidase II; 24Sα, 24Sα-ribosomal DNA; MTq, multiplex TaqMan Real-Time PCR.](pntd.0003765.g001){#pntd.0003765.g001}

Analytical Performance of the Multiplex Real-Time PCR Assays {#sec012}
------------------------------------------------------------

In order to characterize the performance of the MTq-PCR, several analytical parameters were determined \[[@pntd.0003765.ref040]\].

The inclusivity of the assays was evaluated using 0.05--5 ng/μL of genomic DNA obtained from a panel of 39 *T*. *cruzi* stocks belonging to the six DTUs from different geographic origins ([Table 1](#pntd.0003765.t001){ref-type="table"}). On the other hand, 1--5 ng/μL of genomic DNA obtained from *T*. *rangeli*, *L*. *major*, *L*. *amazonensis*, *L*. *brasiliensis* and *L*. *mexicana*, was used to assess the specificity of the assays. Specificity was also tested using human DNA from a seronegative patient as template.

Analytical sensitivity and reaction efficiency were evaluated using 2-fold, 10-fold and 100-fold serial dilutions spanning 1 μg to 1 fg of genomic DNA per reaction tube obtained from *T*. *cruzi* stocks belonging to different DTUs, depending on the assay. Moreover, in the case of TcI, four stocks representing TcIa, TcIb, TcId and TcIe genotypes based on the polymorphism of the SL-IR gene were analyzed \[[@pntd.0003765.ref030]\]. In addition, in the case of TcIV, DNA from strains representing populations from South America (TcIV-SA) and North America (TcIV-NA) were used \[[@pntd.0003765.ref046]\]. Each concentration was tested in duplicate.

Results {#sec013}
=======

Analytical Performance of the Multiplex Real-Time PCR Assays {#sec014}
------------------------------------------------------------

[Fig 1](#pntd.0003765.g001){ref-type="fig"} illustrates the MTq-PCR flowchart designed to distinguish among the six *T*. *cruzi* DTUs.

Inclusivity and specificity results are shown in [Table 3](#pntd.0003765.t003){ref-type="table"}. *T*. *cruzi* I, including stocks representing SL-IR genotypes TcIa, TcIb, TcId and TcIe, were detected by the FAM fluorescence signal in the SL-IR MTq-PCR assay and did not amplify in the downstream reactions of the flowchart. The TcII/V/VI group was detected with the HEX-labeled probe in the SL-IR MTq-PCR. The 18S-COII MTq-PCR assay distinguished TcII (FAM + Cy5 signals) from TcV (HEX signal) and TcVI (FAM signal only). There were two groups of TcIII strains, one group reacted only with the SL-IR TcIII-Quasar670 probe, and the other one composed by three strains (from Brazil, Paraguay and Argentina), reacted with both TcIII-Quasar670 and TcIV-CAL Fluor Red610 SL-IR probes. Thus, the latter group of strains was identified as TcIII after a second round of amplification using the 24Sα-FAM probe. CAL Fluor Red610 and HEX fluorescence signals were detected when the assay contained DNA from TcIV-SA and TcIV-NA strains in the SL-IR and the 24Sα-III/IV MTq-PCR assays, respectively.

10.1371/journal.pntd.0003765.t003

###### Inclusivity and specificity assays for the multiplex real-time PCR genotyping algorithm.
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  Strain         Species                     DTU     SL-IR MTq PCR assay   18S-COII MTq PCR assay   24Sα-III/IV MTq PCR assay                                                               
  -------------- --------------------------- ------- --------------------- ------------------------ --------------------------- ----------- ----------- ----------- ----------- ----------- -----------
  G              *T*. *cruzi*                TcI     **14.11**             neg                      neg                         neg         neg         neg         neg         neg         neg
  K-98           *T*. *cruzi*                TcI     **17.98**             neg                      neg                         nd          nd          nd          nd          nd          nd
  PalDa30        *T*. *cruzi*                TcI     **22.97**             neg                      neg                         nd          nd          nd          nd          nd          nd
  SE9V           *T*. *cruzi*                TcI     **21.04**             neg                      neg                         nd          nd          nd          nd          nd          nd
  TCC            *T*. *cruzi*                TcI     **22.52**             neg                      neg                         nd          nd          nd          nd          nd          nd
  13379 cl7      *T*. *cruzi*                TcI     **38.68**             neg                      neg                         nd          nd          nd          nd          nd          nd
  Sylvio X10     *T*. *cruzi*                TcI     **12.53**             neg                      neg                         nd          nd          nd          nd          nd          nd
  Triatoma       *T*. *cruzi*                TcI     **13.93**             neg                      neg                         nd          nd          nd          nd          nd          nd
  Duran          *T*. *cruzi*                TcI     **11.10**             neg                      neg                         nd          nd          nd          nd          nd          nd
  Gamma          *T*. *cruzi*                TcI     **11.42**             neg                      neg                         nd          nd          nd          nd          nd          nd
  Colombiana     *T*. *cruzi*                TcI     **23.35**             neg                      neg                         nd          nd          nd          nd          nd          nd
  Dm28c          *T*. *cruzi*                TcI     **16.69**             neg                      neg                         nd          nd          nd          nd          nd          nd
  OPS21cl11      *T*. *cruzi*                TcI     **35.52**             neg                      neg                         nd          nd          nd          nd          nd          nd
  Tu18           *T*. *cruzi*                TcII    neg                   **15.16**                neg                         neg         **19.79**   neg         **19.24**   neg         neg
  Basileu        *T*. *cruzi*                TcII    neg                   **29.05**                neg                         neg         **23.38**   neg         **26.15**   nd          nd
  Y              *T*. *cruzi*                TcII    neg                   **26.14**                neg                         neg         **20.92**   neg         **20,71**   nd          nd
  MAS cl1        *T*. *cruzi*                TcII    neg                   **16.31**                neg                         neg         **20.15**   neg         **19,13**   nd          nd
  M5631          *T*. *cruzi*                TcIII   neg                   neg                      **18.55**                   neg         neg         **17.07**   neg         **20.32**   neg
  Ll51-P24-Ro    *T*. *cruzi*                TcIII   neg                   neg                      **33.67**                   **32.59**   nd          nd          nd          **25.96**   neg
  M6241 cl6      *T*. *cruzi*                TcIII   neg                   neg                      **20.17**                   neg         nd          nd          nd          **18.34**   neg
  3663           *T*. *cruzi*                TcIII   neg                   neg                      **38.75**                   **34.21**   nd          nd          nd          **25.14**   neg
  X109/2         *T*. *cruzi*                TcIII   neg                   neg                      **31.26**                   **23.34**   nd          nd          nd          **17.96**   neg
  CanIII         *T*. *cruzi*                TcIV    neg                   neg                      neg                         **17.62**   neg         **38.19**   neg         neg         **24.42**
  4167           *T*. *cruzi*                TcIV    neg                   neg                      neg                         **15.44**   nd          nd          nd          neg         **23.15**
  Griffin        *T*. *cruzi*                TcIV    neg                   neg                      neg                         **33.57**   nd          nd          nd          neg         **31.98**
  Dog Theis      *T*. *cruzi*                TcIV    neg                   neg                      neg                         **14.12**   nd          nd          nd          neg         **23.84**
  92122102R      *T*. *cruzi*                TcIV    neg                   neg                      neg                         **13.92**   nd          nd          nd          neg         **25.57**
  PAH265         *T*. *cruzi*                TcV     neg                   **24.09**                neg                         neg         neg         **24.11**   neg         **27.39**   neg
  PAH179         *T*. *cruzi*                TcV     neg                   **20.46**                neg                         neg         neg         **20.39**   neg         nd          nd
  LL014-1R1cl1   *T*. *cruzi*                TcV     neg                   **33.15**                neg                         neg         neg         **34.64**   neg         nd          nd
  MN cl2         *T*. *cruzi*                TcV     neg                   **20.83**                neg                         neg         neg         **18.67**   neg         nd          nd
  SO3 cl5        *T*. *cruzi*                TcV     neg                   **26.06**                neg                         neg         neg         **26.32**   neg         nd          nd
  CL Brener      *T*. *cruzi*                TcVI    neg                   **16.49**                neg                         neg         **21.92**   neg         neg         neg         neg
  RA             *T*. *cruzi*                TcVI    neg                   **27.88**                neg                         neg         **27.56**   neg         neg         nd          nd
  Tep7           *T*. *cruzi*                TcVI    neg                   **20.20**                neg                         neg         **19.24**   neg         neg         nd          nd
  Tep6 cl5       *T*. *cruzi*                TcVI    neg                   **20.31**                neg                         neg         **21.63**   neg         neg         nd          nd
  LL052          *T*. *cruzi*                TcVI    neg                   **28.01**                neg                         neg         **30.82**   neg         neg         nd          nd
  Tulahuen cl2   *T*. *cruzi*                TcVI    neg                   **35.15**                neg                         neg         **36.16**   neg         neg         nd          nd
  Peruana        *T*. *cruzi*                TcVI    neg                   **29.6**                 neg                         neg         **29.23**   neg         neg         nd          nd
  444            *T*. *rangeli*              \-      neg                   neg                      neg                         neg         neg         neg         neg         neg         neg
  SC-58          *T*. *rangeli*              \-      neg                   neg                      neg                         neg         neg         neg         neg         neg         neg
  Tre            *T*. *rangeli*              \-      neg                   neg                      neg                         neg         neg         neg         neg         neg         neg
  Lmex           *Leishmania mexicana*       \-      neg                   neg                      neg                         neg         neg         neg         neg         neg         neg
  La             *Leishmania amazonensis*    \-      neg                   neg                      neg                         neg         neg         neg         neg         neg         neg
  Lm             *Leishmania major*          \-      neg                   neg                      neg                         neg         neg         neg         neg         neg         neg
  Lb             *Leishmania brasiliensis*   \-      neg                   neg                      neg                         neg         neg         neg         neg         neg         neg
  Human DNA      *Homo sapiens*              \-      neg                   neg                      neg                         neg         neg         neg         neg         neg         neg

Cycle threshold (Ct) values obtained for each TaqMan probe in the analysis of *T*. *cruzi*, *T*. *rangeli* and *Leishmania* sp. stocks and human DNA. 0.1--10 ng of each *T*. *cruzi* strain and 2--10 ng of *T*. *rangeli* and *Leishmania* spp. stocks were used in the reaction tube.

DTU, Discrete Typing Unit; neg, negative; nd, not done.

TcV was amplified and detected with the FAM probe in the 24Sα-III/IV MTq-PCR assay. Besides, TcIII and TcIV were also detected with the 18S-HEX probe in the 18S-COII MTq-PCR. Specificity of the MTq-PCR was not affected since all these DTUs are confirmed in a previous stage.

On the other hand, MTq-PCR was tested with purified DNA from *T*. *rangeli*, *L*. *amazonensis*, *L*. *major* and *L*. *mexicana* stocks and from a seronegative patient. No detectable fluorescence signals were obtained for any of them, indicating the specificity of the assays ([Table 3](#pntd.0003765.t003){ref-type="table"}).

Analytical sensitivity and reaction efficiency were estimated separately for each of the three MTq-PCR reactions using genomic DNA from reference stocks representing the six *T*. *cruzi* DTUs: TcIa (K98), TcIb (Cas16), TcId (G), TcIe (PALV1 cl1), TcII (Tu18), TcIII (M5631), TcIV-SA (CanIII), TcIV-NA (Griffin), TcV (PAH265) and TcVI (CL-Brener). The SL-IR MTq-PCR yielded a positive result starting from 1 fg DNA/reaction tube of TcI reference strains with an efficiency (Eff) of 108% (TcIa), 104% (TcIb), 99% (TcId) and 98% (TcIe). Similar sensitivity was obtained for strains representing TcII (Eff: 90%) and TcIII (Eff: 97%). In the cases of TcIV-SA, TcV and TcVI, sensitivity was lower (1 pg DNA/reaction tube) with Eff of 80%, 88% and 86%, respectively ([Fig 2](#pntd.0003765.g002){ref-type="fig"}). The 18S-COII MTq-PCR reaction rendered a sensitivity of 100 fg DNA/reaction tube for strains representing TcV (Eff: 82%) and TcVI (Eff: 83%) and 1 pg DNA/reaction tube for TcII (Eff: 77% and 70% using the 18S-FAM and the COII-Cy5, respectively) ([Fig 3A](#pntd.0003765.g003){ref-type="fig"}). The 24Sα-III/IV MTq-PCR method was capable of detecting 100 fg DNA/reaction tube of the TcIII (Eff: 92%) and TcIV-SA (Eff: 81%) stocks, whereas TcIV-NA was detected at concentrations ≥ 1 ng/reaction tube (Eff: 78%) ([Fig 3B](#pntd.0003765.g003){ref-type="fig"}).

![Linear range and analytical sensitivity of the first round SL-IR MTq PCR for *T*. *cruzi* DTUs and TcI SL-IR genotypes.\
X-axis represents serial dilutions of whole genomic DNA from each stock and Y-axis represents the obtained Ct value. Linear regression analysis, equation and R^2^ are shown for each graph. Inserts inside plots represent the Ct values obtained for the complete DNA concentration range tested (1 fg---10 ng/ reaction tube). TcIa, strain K98; TcIb, strain Cas16; TcId, strain G; TcIe, strain PALV1 cl1; TcII, strain Tu18; TcIII, strain M5631; TcIV, strain CanIII; TcV, strain PAH265; and TcVI, strain CL Brener.](pntd.0003765.g002){#pntd.0003765.g002}

![Linear range and analytical sensitivity of the second round multiplex real-time PCR tests.\
**A.** 18S-COII MTq PCR assay for reference stocks representing *T*. *cruzi* DTUs TcII, TcV and TcVI. Detection of TcII stock is shown for both TaqMan probes 18S-FAM and COII-Cy5. **B.** 24Sα MTq PCR for reference stocks representing *T*. *cruzi* DTUs TcIII, TcIV-SA and TcIV-NA. X-axis represents serial dilutions of whole genomic DNA from each stock and Y-axis represents the obtained Ct value. Linear regression analysis, equation and R^2^ are shown for each graph. TcII, strain Tu18; TcV, strain PAH265; TcVI, strain CL Brener; TcIII, strain M5631; TcIV-SA (TcIV from South America), strain CanIII; TcIV-NA (TcIV from North America), strain Griffin.](pntd.0003765.g003){#pntd.0003765.g003}

Evaluation of the Multiplex Real-Time PCR Assays in Biological Samples {#sec015}
----------------------------------------------------------------------

A total of 307 biological specimens, including clinical samples (n = 132) as well as samples obtained from different species of vectors (n = 104) and mammal reservoirs (n = 71) from different endemic regions were evaluated using MTq-PCR and a conventional PCR based strategy \[[@pntd.0003765.ref011], [@pntd.0003765.ref017]\].

### Clinical samples {#sec016}

Chagas disease patients were classified into five groups according to their infection phase or infection route: AI, ACD, SCD, CI and RCD (see [Materials and Methods](#sec005){ref-type="sec"}). From one RCD patient, more than one sample (blood and skin biopsy samples) was available for analysis. The AI group included 10 peripheral blood samples from people who acquired the infection in oral outbreaks in the Amazon region of Bolivia, Venezuela, Colombia and French Guiana; one sample from a vector-transmitted acute patient from Chiapas, Mexico; and two samples from patients who acquired *T*. *cruzi* infection due to organ transplantation. The MTq-PCR was able to characterize DTUs in all AI samples, in total agreement with the conventional techniques, confirming 5 TcI and 6 TcIV cases ([Table 4](#pntd.0003765.t004){ref-type="table"} and [S1 Table](#pntd.0003765.s001){ref-type="supplementary-material"}). In two samples, conventional PCR was not able to discriminate between pure TcV infections or a mixture of TcV plus TcVI. However, the MTq-PCR confirmed TcV, allowing exclusion of TcVI ([Table 4](#pntd.0003765.t004){ref-type="table"} and [S1 Table](#pntd.0003765.s001){ref-type="supplementary-material"}).

10.1371/journal.pntd.0003765.t004

###### Multiplex real-time PCR genotyping algorithm validation with biological samples.

![](pntd.0003765.t004){#pntd.0003765.t004g}

  Samples                 Conventional PCR pos                                       MTq PCR pos   TcI   TcII/V/VI   TcII/VI   TcII   TcIII   TcIV   TcV   TcVI   Mixed infections   
  ----------------------- ---------------------------------------------------------- ------------- ----- ----------- --------- ------ ------- ------ ----- ------ ------------------ -----------------------------------------
  **Human**               **AI**                                                     13            13    5           0         0      0       0      6     2      0                  0
                          **ACD**                                                    64            21    19          0         1      0       0      0     1      0                  0
                          **SCD**                                                    27            6     6           0         0      0       0      0     0      0                  0
                          **CI**                                                     16            10    1           1         1      0       0      0     6      0                  1[^d^](#t004fn004){ref-type="table-fn"}
                          **RCD** [^a^](#t004fn002){ref-type="table-fn"}             12            6     3           0         1      1       0      0     1      0                  0
  **Vectors**             **Direct sample** [^b^](#t004fn003){ref-type="table-fn"}   88            71    47          0         0      1       5      8     1      0                  9[^e^](#t004fn005){ref-type="table-fn"}
                          **Culture**                                                16            15    11          0         0      0       0      4     0      0                  0
  **Animal reservoirs**   **Direct sample** [^c^](#t004fn004){ref-type="table-fn"}   44            41    40          0         0      0       0      0     0      0                  1[^f^](#t004fn006){ref-type="table-fn"}
                          **Culture**                                                27            27    3           0         6      0       16     2     0      0                  0
  **Total**               307                                                        210           135   1           0         3      21      20     11    8      11                 

Positive results obtained with the Real-Time and conventional PCR assays for the DTU characterization of biological samples were compared. The number of samples belonging to each DTU group corresponds to the Real-Time PCR algorithm results.

^a^Eleven peripheral blood samples and one skin biopsy sample

^b^Sixty three urine/feces samples on filter paper and 25 abdomen/tissue samples

^c^Forty peripheral blood and 4 heart explant samples; pos, positive results. Mixed infections were characterized as ^d^TcV plus TcVI,

^e^6 TcI plus TcIV, 1 TcI plus TcIII/IV and 2 TcIII plus TcIV,

^f^TcI plus TcII. AI, acute *T*. *cruzi* infection; ACD, asymptomatic chronic Chagas disease; SCD, symptomatic chronic Chagas disease; CI, congenitally infected children; and RCD, patients with reactivation in the context of immunosuppression.

The DTUs present in 10 out of 16 (62.5%) peripheral blood samples analyzed from CI children could be identified by the MTq-PCR. Results were clearly consistent with those obtained by the conventional strategies, confirming 1 TcI and 4 TcV infections ([Table 4](#pntd.0003765.t004){ref-type="table"} and [S1 Table](#pntd.0003765.s001){ref-type="supplementary-material"}). In 4 samples, conventional PCR was not able to discriminate between pure TcV infections or a mixture of TcV plus TcVI. However, the MTq-PCR confirmed TcV in two cases, classified one as an indeterminate TcII/V/VI sample, and classified the remaining one as a mixed infection of TcV plus TcVI. Furthermore, one sample that was classified as indeterminate TcII/V/VI using the conventional PCR algorithm was classified as TcVI using the MTq-PCR ([Table 4](#pntd.0003765.t004){ref-type="table"} and [S1 Table](#pntd.0003765.s001){ref-type="supplementary-material"}).

Eleven peripheral blood samples and one skin biopsy sample from RCD patients were analyzed and six (50%) could be genotyped by MTq-PCR, confirming three as infected with TcI populations ([Table 4](#pntd.0003765.t004){ref-type="table"} and [S1 Table](#pntd.0003765.s001){ref-type="supplementary-material"}). In one sample, conventional PCR was not able to discriminate between pure TcV or a mixture of TcV plus TcVI. However, MTq-PCR confirmed TcV and excluded TcVI. Additionally, the skin biopsy sample was classified as doubtful TcII/VI by the conventional PCR, but MTq-PCR confirmed the presence of TcII DNA. On the other hand, *T*. *cruzi* populations in the peripheral blood sample of the above mentioned patient were confirmed as belonging to TcII by the conventional method and classified as indeterminate TcII/VI by MTq-PCR ([Table 4](#pntd.0003765.t004){ref-type="table"} and [S1 Table](#pntd.0003765.s001){ref-type="supplementary-material"}).

A low proportion of chronic Chagas disease patients' samples (32.8% ACD and 22.2% SCD) could be characterized by the MTq-PCR, and most of them were typed as TcI (n = 25), in full accordance with conventional typing ([Table 4](#pntd.0003765.t004){ref-type="table"} and [S1 Table](#pntd.0003765.s001){ref-type="supplementary-material"}). In one sample, conventional PCR was not able to discriminate between pure TcV infection or a mixture of TcV plus TcVI. However, TaqMan PCR confirmed TcV and eliminated TcVI. On the other hand, another sample was confirmed as TcVI by the conventional PCR method and classified as indeterminate TcII/VI by the MTq-PCR ([Table 4](#pntd.0003765.t004){ref-type="table"} and [S1 Table](#pntd.0003765.s001){ref-type="supplementary-material"}).

### Triatomine samples {#sec017}

A total of 104 samples (88 direct samples and 16 culture isolates) obtained from urine, feces and tissue (midgut/abdomen) specimens from triatomines were processed. The MTq-PCR gave positive results in 80.7% and 93.8% of direct samples and isolated cultures, respectively, confirming 54 TcI, 1 TcII, 2 TcIII and 8 TcIV (Tables [4](#pntd.0003765.t004){ref-type="table"} and [S2](#pntd.0003765.s002){ref-type="supplementary-material"}). Overall typed vector samples, two indeterminate TcIII (or TcIII plus TcI) and one TcV (or TcV plus TcVI) specimens by the conventional methods were confirmed as TcIII, TcI and TcV, respectively, by the MTq-PCR (Tables [4](#pntd.0003765.t004){ref-type="table"} and [S2](#pntd.0003765.s002){ref-type="supplementary-material"}).

### Reservoir samples {#sec018}

The study included 71 samples (44 direct samples and 27 culture isolates) obtained from peripheral blood and tissue specimens from mammal reservoirs of *T*. *cruzi*, most of which were successfully typified by MTq-PCR (100% of culture isolates and 93.2% of direct samples), confirming 28 TcI, 16 TcIII and 1 TcIV (Tables [4](#pntd.0003765.t004){ref-type="table"} and [S3](#pntd.0003765.s003){ref-type="supplementary-material"}). Six TcVI samples obtained from peripheral blood of *Canis familiaris* were classified as indeterminate TcII/VI by MTq-PCR (Tables [4](#pntd.0003765.t004){ref-type="table"} and [S3](#pntd.0003765.s003){ref-type="supplementary-material"}).

### Analysis of mixed infections {#sec019}

In clinical samples, a mixed infection by TcI plus TcII/V/VI found in a SCD patient gave no amplification after SL-IR MTq-PCR, probably because of its very low parasitic load \[[@pntd.0003765.ref047]\].

Detection of DTU-mixed infections in vector samples revealed a complex situation, in which MTq-PCR succeeded in resolving six out of 16 mixtures previously characterized by the conventional PCR tests; nine were characterized as single infections and one gave negative results (Tables [4](#pntd.0003765.t004){ref-type="table"} and [S2](#pntd.0003765.s002){ref-type="supplementary-material"}). On the other hand, three samples that were classified as inconclusive TcIII (or TcIII plus TcI) using conventional PCR were classified as mixed infections using MTq-PCR (2 TcIII plus TcIV and 1 TcI plus TcIII/IV) (Tables [4](#pntd.0003765.t004){ref-type="table"} and [S2](#pntd.0003765.s002){ref-type="supplementary-material"}).

In the case of reservoir samples, MTq-PCR confirmed one case of TcI plus TcII mixed infection but failed to resolve 17 other mixed infections previously characterized in *Didelphis virginiana*, *Macaca fascicularis*, *Canis familiaris* and *Felis catus* by conventional PCR (Tables [4](#pntd.0003765.t004){ref-type="table"} and [S3](#pntd.0003765.s003){ref-type="supplementary-material"}).

Discussion {#sec020}
==========

As a consequence of the standardized nomenclature for the six *T*. *cruzi* DTUs having been ratified by a committee of experts \[[@pntd.0003765.ref006]\], it became imperative to develop a reliable genotyping strategy that could be adopted by the research community \[[@pntd.0003765.ref008]\]. Throughout the past years, several typing schemes have been developed. A PCR assay system based on the amplification of particular regions of the SL gene and 24Sα-rDNA \[[@pntd.0003765.ref044]\] and 18S rDNA \[[@pntd.0003765.ref048]\] was first proposed \[[@pntd.0003765.ref015]\] in which the size polymorphisms of the amplification products were suitable for *T*. *cruzi* assignment into each of the six DTUs. A multilocus PCR-RFLP analysis of genetic polymorphism of 12 loci also was proposed for DTU genotyping \[[@pntd.0003765.ref016]\]. Additionally, a three-marker sequential typing strategy was proposed consisting of PCR amplification of the 24Sα-rDNA and PCR-RFLP of the heat shock protein 60 and glucose-6-phosphate isomerase loci \[[@pntd.0003765.ref018]\]. Yeo et al. (2011) and Lauthier et al. (2012) designed Multilocus Sequence Typing (MLST) schemes in which sequence information of 4 to 10 single copy housekeeping genes allowed the resolution of the six DTUs \[[@pntd.0003765.ref021]--[@pntd.0003765.ref022]\]. A recent assay that uses a single copy gene (TcSC5D) followed by two RFLP reactions has been reported \[[@pntd.0003765.ref023]\]. However, most of the above mentioned assays are complex to perform and have been applied only to cultured parasites. Another scheme using nested-hot-start PCR assays allows direct DTU typing in biological \[[@pntd.0003765.ref025], [@pntd.0003765.ref049]\] and clinical \[[@pntd.0003765.ref011], [@pntd.0003765.ref017]\] samples but requires between 3 and 9 sequential PCR reactions.

To overcome these difficulties we developed a novel MTq-PCR approach that identifies the six *T*. *cruzi* DTUs in a single or two sequential reactions with adequate sensitivity to analyze different types of biological samples, such as those derived from triatomine vectors and different type of wildlife, livestock, pets and human tissues. The Real-Time format reduces PCR associated contamination and is amenable to quantification, automation and kit production. A first round allows distinction of TcI strains from those belonging to TcIII/IV or TcII/V/VI groups, which are discriminated after a second MTq-PCR round. The method was inclusive for a panel of 39 *T*. *cruzi* stocks. In particular, the TcI primer/probe set was inclusive for all TcI SL-IR genotypes \[[@pntd.0003765.ref030]\], and the TcIV primer/probe set was inclusive for TcIV strains from South and North America \[[@pntd.0003765.ref046]\]. Besides, the test did not recognize human, *T*. *rangeli* and *Leishmania* spp. DNAs.

MTq-PCR methods showed an analytical sensitivity ranging from 1 fg to 1 pg DNA per reaction tube depending on the DTU being analyzed. As an exception, TcIV-NA was detected at concentrations ≥ 1 ng/reaction tube by the 24Sα-III/IV MTq-PCR. The analytical sensitivity for the conventional PCR scheme used in this study was reported in Burgos et al. (2007) \[[@pntd.0003765.ref017]\] and ranged from 100 fg to 10 pg DNA per reaction tube depending on the reaction and the DTU under analysis. Thus, both PCR algorithms used in the present study showed similar ranges of sensitivity when compared at analytical levels.Out of 210 biological samples that could be typed by both algorithms, 24 (11.4%) gave inconclusive TcII/V/VI, TcII/VI, TcV (or TcV plus TcVI) and TcIII (or TcIII plus TcI) results by either conventional or MTq-PCR. In nine samples, conventional PCR was not able to discriminate between single TcV infection and a mixture of TcV plus TcVI. However, MTq-PCR confirmed TcV in seven of these samples thanks to specific detection of the 18S-HEX probe. One sample, typed as TcII/V/VI by conventional PCR, could be resolved as TcII/VI by MTq-PCR. Furthermore, an indeterminate TcII/VI and 2 TcIII (or TcIII plus TcI) samples were confirmed as TcII, TcI and TcIII, respectively, by MTq-PCR ([S1](#pntd.0003765.s001){ref-type="supplementary-material"}--[S3](#pntd.0003765.s003){ref-type="supplementary-material"} Tables). On the other hand, 7 TcVI and one TcII samples typed by the conventional PCR algorithm were classified as indeterminate TcII/VI by the MTq-PCR ([S1](#pntd.0003765.s001){ref-type="supplementary-material"}--[S3](#pntd.0003765.s003){ref-type="supplementary-material"} Tables).

Finally, both algorithms confirmed mixed infections in one patient from Jujuy, Argentina (TcV plus TcVI), in one cat from Mexico (TcI plus TcII) and in several sylvatic vector species, such as TcI plus TcIII, TcI plus TcIV and TcIII plus TcIV ([S1](#pntd.0003765.s001){ref-type="supplementary-material"}--[S3](#pntd.0003765.s003){ref-type="supplementary-material"} Tables). In general the MTq-PCR detected mixed infections in a lesser extent than the conventional PCR scheme. Oligonucleotide interactions, competition for reagents, different amplification efficiency of the targets, and accumulation of amplicons of the predominant target that inhibit Taq polymerase are factors that might be involved.

The MTq-PCR test was less sensitive than conventional PCR algorithm for direct typing of peripheral blood samples of a proportion of chronic Chagas disease patients harboring low parasite loads. We have evaluated the analytical sensitivity of the assay using mixtures of *T*. *cruzi* DNA with DNA extracted from human blood from non-infected subjects and no differences in analytical sensitivity were found ([S1 Fig](#pntd.0003765.s004){ref-type="supplementary-material"}). This suggests that the lower clinical sensitivity of the assay in blood samples would not be due to inhibitory substances present in the samples. In some human cases tested in this study, we can not discard some DNA degradation with respect to the period where the extracts were analyzed using conventional PCR algorithm \[[@pntd.0003765.ref050]\].

The findings herein obtained, promote MTq-PCR as a valuable laboratory tool for distinction of *T*. *cruzi* DTUs. It appears adequate in surveillance and identification of outbreaks sources \[[@pntd.0003765.ref051]\] or to follow-up acute infections of seronegative recipients that receive infected organs from seropositive donors \[[@pntd.0003765.ref052]\].
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###### Linear range and analytical sensitivity of the first round SL-IR MTq PCR for a TcIa representative stock in both presence and absence of 38 ng DNA extracted from human blood from non-infected subjects.

X-axis represents serial dilutions of whole genomic DNA and Y-axis represents the obtained Ct value. TcIa, strain K98.
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